Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial

The Lancet Infectious Diseases

Volumn 14, Issue 7, 2014, Pages 581-589

  Arribas, Jose R ^a   Pialoux, Gilles ^b   Gathe, Joseph ^c   Di Perri, Giovanni ^d   Reynes, Jacques ^e   Tebas, Pablo ^f   Nguyen, Thai ^g   Ebrahimi, Ramin ^g   White, Kirsten ^g   Piontkowsky, David ^g  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b SORBONNE UNIVERSITÉ   (France)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TURIN   (Italy)

^e GUI DE CHAULIAC HOSPITAL   (France)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; CREATININE; DARUNAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR; LOPINAVIR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; ALGORITHM; ANTIVIRAL THERAPY; ANXIETY; ARTICLE; BIPOLAR DISORDER; BLOATING; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HEADACHE; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; INTENTION TO TREAT ANALYSIS; LIVER METASTASIS; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SUICIDE ATTEMPT; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD; BACKACHE; DEPRESSION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; OUTCOME ASSESSMENT; TREATMENT DURATION;

ADENINE; ADULT; ANTI-HIV AGENTS; CARBAMATES; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PROTEASE INHIBITORS; QUINOLONES; RITONAVIR; THIAZOLES; VIRAL LOAD;

EID: 84904698918     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70782-0     Document Type: Article

References (29)

1. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services, 2014 Panel on Antiretroviral Guidelines for Adults and Adolescents, (accessed May 22, 2014). http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
2. EACS guidelines version 7.0. European AIDS Clinical Society, 2013 European AIDS Clinical Society, (accessed on March 25, 2014). http://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf.
3. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA Panel. JAMA 2012, 308:387-402.
4. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723-1735. The DAD Study Group.
5. Boesecke C, Cooper DA Toxicity of HIV protease inhibitors: clinical considerations. Curr Opin HIV AIDS 2008, 3:653-659.
6. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010, 375:396-407. for the SWITCHMRK 1 and 2 investigators.
7. Martinez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010, 24:1697-1707. for the SPIRAL Study Group.
8. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012, 379:2439-2448. for the GS-US-236-0102 study team.
9. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012, 379:2429-2438. for the GS-236-0103 Study Team.
10. Wohl D, Cohen C, Gallant JE, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) demonstrates durable efficacy and favorable long-term safety profile versus efavirenz/emtricitabine/tenofovir DF (ATR) at week 144 in treatment-naive HIV patients. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Denver, CO, USA; Sept 10-13, 2013. H-672A.
11. Clumeck N, Molina JM, Henry K, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in treatment-naïve HIV-1 infected patients: week 144 results. 14th European AIDS Conference; Brussels, Belgium; Oct 16-19, 2013. LBPS7/2.
12. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2014, 15(suppl 1):1-85.
13. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV infected patients. HIV Clin Trials 2002, 3:371-378.
14. Stone VE, Jordan J, Tolson J, Miller R, Pilon T Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004, 36:808-816.
15. Smith F, Hammerstrom T, Soon G, et al. A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Inf J 2011, 45:291-300.
16. Guidance for industry: E9 statistical principles for clinical trials. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, 1998 US DHSS, FDAFDA, CDERCDER, CBERCBER, (accessed April 29, 2014). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073137.pdf.
17. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements-clinical considerations for accelerated and traditional approval. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2002 US DHSS, FDAFDA, CDERCDER, CBERCBER, (accessed March 25, 2014). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070968.pdf.
18. Chan IS, Zhang Z Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics 1999, 55:1202-1209.
19. Cockcroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
20. COMPLERA (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets, for oral use. US prescribing information. Foster City: Gilead Sciences, 2013 Gilead Sciences, (accessed May 22, 2014). http://www.gilead.com/~/media/Files/pdfs/medicines/hiv/complera/complera_pi.PDF.
21. Palella FJ, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS 2014, 28:335-344.
22. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 2012, 61:32-40.
23. Stray KM, Bam RA, Birkus G, et al. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. Antimicrob Agents Chemother 2013, 57:4982-4989.
24. Hodder SL, Mounzer K, DeJesus E, et al. Patient-reported outcomes after simplification to a single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS 2010, 24:87-96. for the AI266073 Study Group.
25. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010, 4:115-125.
26. Bangsberg DR, Ragland K, Monk A, Deeks SG A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 2010, 24:2835-2840.
27. Cohen CJ, Meyers JL, Davis KL Association between daily antiretroviral pill burden and treatment adherence, hospitalization risk, and other health utilisation and costs in a US medicaid population with HIV. BMJ Open 2013, 3:e003028.
28. Llibre JM, Arribas JR, Domingo P, et al. Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. AIDS 2011, 25:1683-1690.
29. Pozniak A, Markowitz M, Mills A, et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGTY-NNRTI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 2014, published online June 5. http://dx.doi.org/10.1016/S1473-3099(14)70796-0.